Preapproval and postapproval evidence on drugs for multiple sclerosis

Area of Science:

• Neurology
• Pharmacology
• Clinical Research

Background:

• Multiple sclerosis (MS) treatments have expanded, necessitating an evaluation of supporting evidence and postmarketing research.
• The European Union marketing authorization process for MS drugs requires review of pre-approval data and post-approval research quality.

Purpose of the Study:

• To review evidence supporting European Union marketing authorization for multiple sclerosis (MS) drugs.
• To assess how postmarketing research addresses information gaps present at the time of drug approval.

Main Methods:

• Identified drugs approved by the European Medicines Agency for MS.
• Analyzed pivotal trials and searched for postmarketing randomized controlled trials (RCTs) for 8 approved MS drugs.
• Examined trial outcomes, particularly regarding relapse rates and disability progression.

Main Results:

• Eight MS drugs were included, analyzed via 16 pivotal trials with nearly 16,000 participants.
• Fifty-two postmarketing trials were identified; 24 reported results, while 28 were ongoing or had unavailable results.
• No direct comparative studies between approved MS drugs were found, and data on preventing disability progression were scarce.

Conclusions:

• Lack of comparative evidence and clinical effectiveness data impedes assessing the therapeutic value of approved MS drugs.
• The current postmarketing research landscape for MS treatments leaves significant questions about optimal drug selection and patient outcomes unanswered.